🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Banks aim for sale of Ratiopharm as whole -sources

Published 09/16/2009, 08:00 AM
Updated 09/16/2009, 08:03 AM
SASY
-
HEIG
-
TGT
-

FRANKFURT, Sept 16 (Reuters) - Banks controlling the sale of Ratiopharm plan to put the German generic drugmaker on offer as a whole, two people familiar with the sale process told Reuters on Wednesday, rejecting a report that a break-up was imminent.

The lenders, keen to use proceeds from the sale to recoup some of the debt owed by Ratiopharm's founding Merckle family, expect to fetch more for the entire group than if parts are sold separately, one source familiar with their thinking said.

A sale in separate parts cannot be ruled out entirely but the option is seen as intricate because the target would have to be divided up without overlap or leftovers, the sources said.

An initial public offering (IPO) could also be an option, but it is unlikely because the procedure is much more costly than a sale, one source said.

Ratiopharm declined to comment.

The world's fourth-largest generics supplier is part of the heavily indebted empire built up by German billionaire Adolf Merckle, who killed himself in January after being forced to cede control of his conglomerate to lenders after huge trading losses.

His oldest son, Ludwig Merckle, inherited the main holdings, which include a majority stake in cement maker HeidelbergCement and drug wholesaler Phoenix.

HeidelbergCement this week unveiled plans to raise its capital by half, also saying that Merckle would sell most of his shares in the building materials company.

On Wednesday, German business daily Handelsblatt cited industry sources as saying a sale of Ratiopharm in separate slices was now the most likely option.

The group's Canadian business could be split off and Novartis' generics subsidiary Sandoz was seen as a likely bidder for that asset, the newspaper said, citing sources.

Teva, Sanofi-Aventis and Mylan are tipped as potential suitors for Ratiopharm.

Up to 15 suitors will receive the first documents on the sale in the next few weeks, sources told Reuters.

The procedure is managed by Commerzbank and Royal Bank of Scotland.

(Reporting by Frank Siebelt and Philipp Halstrick, writing by Ludwig Burger; editing by Elaine Hardcastle)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.